ライフサイエンスコーパス: irinotecan

1 toxicity of, SN38 (the active metabolite of irinotecan).

2 isting of a platinum agent plus etoposide or irinotecan.

3 nsitivity to SN-38, the active metabolite of irinotecan.

4 tic index of SN-38, the active metabolite of irinotecan.

5 s active metabolite SN-38 compared with free irinotecan.

6 luding a fluoropyrimidine and oxaliplatin or irinotecan.

7 otype can be used to individualize dosing of irinotecan.

8 n PFS between treatment arms with or without irinotecan.

9 imination of SN-38, the active metabolite of irinotecan.

10 ded dosing on efficacy in patients receiving irinotecan.

11 droxycamptothecin), the active metabolite of irinotecan.

12 ess the distribution of the anticancer drug, irinotecan.

13 FL118 shows structural similarity to irinotecan.

14 rs as a single agent and in combination with irinotecan.

15 stemic chemotherapy including oxaliplatin or irinotecan.

16 and its clinical derivatives, topotecan and irinotecan.

17 n two repeat dose schedules, was superior to irinotecan.

18 ent of malignant glioma with bevacizumab and irinotecan.

19 s systemic chemotherapy with oxaliplatin and irinotecan.

20 icantly enhances the bioavailability of oral irinotecan.

21 ation, particularly with orally administered irinotecan.

22 o those reported with protracted intravenous irinotecan.

23 rontline colorectal cancer chemotherapy drug irinotecan.

24 delivery of SN-38, the active metabolite of irinotecan.

25 osis, and were refractory to oxaliplatin and irinotecan.

26 combinatorial treatment of Pitavastatin and Irinotecan.

27 ther cetuximab monotherapy or cetuximab plus irinotecan.

28 8-a prodrug of the topoisomerase I inhibitor irinotecan.

29 The first group was given irinotecan (100 mg/kg), the second oxaliplatin (5 mg/kg)

30 emotherapy and had relapsed disease received irinotecan 150 mg/m(2) and carboplatin AUC of 5 (arm B).

31 if patients received prior oxaliplatin, then irinotecan 150 mg/m(2) was used).

32 Cetuximab 250 mg/m(2) weekly plus irinotecan 16 mg/m(2)/d (pediatric) or 20 mg/m(2)/d (ado

33 5, 150, 250 mg/m(2)) in a 3 + 3 design, plus irinotecan (16 or 20 mg/m(2)/d) for 5 days for 2 consecu

34 received adjuvant oxaliplatin could receive irinotecan 180 mg/m(2) intravenously over 30 min with fl

35 en 250 mg/m(2) once per week with or without irinotecan 180 mg/m(2) once every 2 weeks.

36 er FOLFIRINOX alone (oxaliplatin 85 mg/m(2), irinotecan 180 mg/m(2), leucovorin 400 mg/m(2), and bolu

37 ay cycle consisted of bevacizumab (5 mg/kg), irinotecan (180 mg/m(2)), bolus FU (400 mg/m(2)), and le

38 receive FOLFIRINOX (oxaliplatin, 85 mg/m(2); irinotecan, 180 mg/m(2); leucovorin, 400 mg/m(2); and fl

39 otecan with vincristine: regimen 1A included irinotecan 20 mg/m(2)/d intravenously for 5 days at week

40 tients with extensive SCLC were treated with irinotecan 200 mg/m(2) and carboplatin area under the cu

41 h fluorouracil (77.1% vs 46.6%, p=0.037) and irinotecan (41.7% vs 24.4%, p=0.006).

42 d with bevacizumab alone or bevacizumab plus irinotecan, 46.4% and 65.8%, respectively, experienced g

43 80 mg/m(2) per day on days 1 to 7 along with irinotecan 50 mg/m(2) intravenously and temozolomide 100

44 of weeks 1, 2, 4, and 5; regimen 1B included irinotecan 50 mg/m(2)/d intravenously for 5 days at week

45 Irinotecan 50 mg/m(2)/day for 5 days was the MTD when co

46 omide (100 mg/m(2) per dose) and intravenous irinotecan (50 mg/m(2) per dose) on days 1-5 of 21-day c

47 population are temozolomide 75 mg/m2/d plus irinotecan 60 mg/m2/d when given with cefixime.

48 the second oxaliplatin (5 mg/kg), the third irinotecan (80 mg/kg) plus oxaliplatin (5 mg/kg), and th

49 A third arm consisting of nanoliposomal irinotecan (80 mg/m(2), equivalent to 70 mg/m(2) of irin

50 Unlike irinotecan, a clinical CES2-activated prodrug, PPD produ

51 with distinct circadian toxicity patterns of irinotecan, a topoisomerase I inhibitor active against c

52 ients with disease known to be responsive to irinotecan achieved partial response.

53 administered at doses 5-fold lower than free irinotecan achieved similar intratumoral exposure of SN-

54 se (MTD) and dose limiting toxicity (DLT) of irinotecan administered in combination with vincristine,

55 Irinotecan administration caused significant delay in th

56 can against HT-29 cells and was as potent as irinotecan against A549 cells in xenograft models.

57 ealed that compound 18a was more potent than irinotecan against HT-29 cells and was as potent as irin

58 We assessed the effect of nanoliposomal irinotecan alone or combined with fluorouracil and folin

59 n with panitumumab) vs 4.4 [2.8-6.7] months (irinotecan alone); HR, 0.38 [95% CI, 0.24-0.61]; P < .00

60 230 patients were randomly allocated to irinotecan and 230 to IrPan.

61 hese lines were tested for their response to irinotecan and a Chk1 inhibitor (either UCN-01 or AZD776

62 ow evidence of drug-drug interaction between irinotecan and alisertib.

63 4 (MRP4), such as the anti-colon cancer drug irinotecan and an anti-retroviral used to treat HIV infe

64 IROX [irinotecan plus oxaliplatin] and IFL [irinotecan and bolus fluorouracil plus leucovorin]).

65 trial to evaluate a novel 21-day schedule of irinotecan and carboplatin in patients with relapsed or

66 This 21-day regimen of irinotecan and carboplatin seems promising for the treat

67 phase II trial evaluating the combination of irinotecan and cetuximab every second week, as third-lin

68 nd 2.8-fold (P < 0.001) in mice treated with irinotecan and combination therapy, respectively.

69 ntified, which potentiated the efficacies of irinotecan and gemcitabine in SW620 human colon carcinom

70 ve higher intratumoral levels of the prodrug irinotecan and its active metabolite SN-38 compared with

71 cted the abundance change of anticancer drug irinotecan and its metabolites inside spheroids treated

72 lism of xenobiotics, including drugs such as irinotecan and oseltamivir.

73 An early example was the appraisal of irinotecan and oxaliplatin for colorectal cancer in 2002

74 FOLFIRINOX (leucovorin and fluorouracil plus irinotecan and oxaliplatin) in patients with locally adv

75 in conjugation by 70% and is associated with irinotecan and protease inhibitor side effects.

76 learance (an inverse measure of exposure) of irinotecan and SN-38 by 37% and 38%, respectively (P < .

77 dose for 7 days is tolerable with a standard irinotecan and temozolomide backbone and has promising r

78 ine the response rate associated with use of irinotecan and temozolomide for children with relapsed/r

79 The combination of irinotecan and temozolomide has activity in these patien

80 Irinotecan and temozolomide have activity in patients wi

81 Irinotecan and temozolomide have single-agent activity a

82 ximum tolerated dose (MTD) of alisertib with irinotecan and temozolomide in this population.

83 as used to randomly assign patients (1:1) to irinotecan and temozolomide plus either temsirolimus or

84 The combination of irinotecan and temozolomide was well tolerated.

85 h a combination of the chemotherapeutic drug irinotecan and the monoclonal antibody cetuximab.

86 o other FDA-approved camptothecin analogues (irinotecan and topotecan).

87 he cancer chemotherapeutics derived from it, irinotecan and topotecan, are highly specific inhibitors

88 All patients had irinotecan and/or oxaliplatin-based chemotherapy before

89 y of 5c with SN-38 (the active metabolite of irinotecan) and 5-fluorouracil on cell proliferation und

90 tween FOLFIRI (fluorouracil, leucovorin, and irinotecan) and ECX (epirubicin, cisplatin,and capecitab

91 For the anticancer drug CPT-11 (irinotecan) and the nonsteroidal anti-inflammatory drug

92 The efficacy of cisplatin, irinotecan, and bevacizumab was evaluated in patients wi

93 a randomized clinical trial of panitumumab, irinotecan, and ciclosporin in colorectal cancer (PICCOL

94 therapy (comprising oxaliplatin, leucovorin, irinotecan, and fluorouracil) in patients with metastati

95 litaxel, oxaliplatin, rituximab, infliximab, irinotecan, and other drugs).

96 of folinic acid (leucovorin), fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX), restrict their

97 tatic setting (eg, fluorouracil, leucovorin, irinotecan, and oxaliplatin and gemcitabine plus nanopar

98 mbinations such as fluorouracil, leucovorin, irinotecan, and oxaliplatin as well as gemcitabine/nab-p

99 OX (fluorouracil, folinic acid [leucovorin], irinotecan, and oxaliplatin) and gemcitabine plus nanopa

100 FOLFIRINOX (leucovorin, fluorouracil, irinotecan, and oxaliplatin; favorable comorbidity profi

101 e combination of a WEE1 inhibitor (AZD1775), irinotecan, and vincristine can lead to complete respons

102 ptothecin and its derivatives, topotecan and irinotecan, are specific topoisomerase I (Top1) inhibito

103 rin, and oxaliplatin (FOLFOX4; arm B) versus irinotecan (arm A).

104 mined in phase II window studies, and use of irinotecan as a radiation sensitizer.

105 cer camptothecins (CPTs) (e.g. topotecan and irinotecan) as well as structurally perturbed DNAs (e.g.

106 Daily oral cefixime was used to reduce irinotecan-associated diarrhea.

107 in at 65 mg/m(2), leucovorin at 400 mg/m(2), irinotecan at 140 mg/m(2), and fluorouracil 400 mg/m(2)

108 e treated with FU/RT plus weekly intravenous irinotecan at 50 mg/m(2).

109 ntinuously days 1 through 35 and intravenous irinotecan at 60 mg/m(2) once weekly weeks 1 to 4.

110 urve (AUCs; r(2) = 0.0003; P = .97), but the irinotecan AUC was correlated with the actual dose (r(2)

111 every 3 weeks, equivalent to 100 mg/m(2) of irinotecan base) or fluorouracil and folinic acid.

112 can (80 mg/m(2), equivalent to 70 mg/m(2) of irinotecan base) with fluorouracil and folinic acid ever

113 antage of bevacizumab was more apparent with irinotecan-based chemotherapy (HR, 0.80; 95% CI, 0.66 to

114 re aggressive intervention (oxaliplatin- and irinotecan-based chemotherapy and/or surgery for recurre

115 ed to be candidates for oxaliplatin-based or irinotecan-based chemotherapy regimens, were randomly as

116 h mCRC treated with bev plus oxaliplatin- or irinotecan-based chemotherapy, and correlated treatment

117 and 2011 and treated with oxaliplatin and/or irinotecan-based preoperative chemotherapy were eligible

118 GLARIUS trial thus explored bevacizumab plus irinotecan (BEV+IRI) as an alternative to TMZ.

119 management of treatment with bevacizumab and irinotecan (BEV/IR) in patients with recurrent high-grad

120 The demonstrated efficacy of adding irinotecan, bevacizumab, or cetuximab to fluorouracil-ba

121 itinib increased the bioavailability of oral irinotecan by four-fold over that observed in historical

122 ur work shows how liposomal encapsulation of irinotecan can safely improve its antitumor activity in

123 with p65 siRNA photothermal transfection and irinotecan caused substantially enhanced tumor apoptosis

124 The ICECREAM (Irinotecan Cetuximab Evaluation and Cetuximab Response E

125 -erbalpha and Bmal1 mRNA expressions and for irinotecan chronotoxicity in clock-altered Per2(m/m) mic

126 Irinotecan clearance followed linear kinetics.

127 The cetuximab/irinotecan combination can be given safely to children a

128 ant KRAS tumors indicated that the anti-DLL4/irinotecan combination produced a significant decrease i

129 ties for the clinical translation of PDT and irinotecan combination therapy for effective pancreatic

130 erval, pretreatment with an 80 mg/kg dose of irinotecan combined with 2 fractions of 4.5 Gy in a 24-h

131 ine the maximum-tolerated dose (MTD) of oral irinotecan combined with temozolomide in children with r

132 ds Eligible patients with at least one prior irinotecan-containing therapy received labetuzumab govit

133 re recruited to a three-arm design including irinotecan (control), irinotecan plus ciclosporin, and i

134 Here, we prepared PEG conjugates of the irinotecan (CPT-11) active metabolite SN-38 via a phenyl

135 orphism, that can explain the variability in irinotecan (CPT-11) pharmacokinetics and neutropenia in

136 expression is associated with resistance to irinotecan (CPT-11) therapy in preclinical colorectal ca

137 A phase II study of bevacizumab (BVZ) plus irinotecan (CPT-11) was conducted in children with recur

138 m are capable of binding the anticancer drug irinotecan (CPT-11) with micromolar affinity.

139 infusion (HAI) plus systemic oxaliplatin and irinotecan (CPT-11).

140 Adding panitumumab to irinotecan did not improve the overall survival of patie

141 ing cassette G2 (ABCG2) transporter-mediated irinotecan efflux from cells.

142 These drugs included topotecan, irinotecan, etoposide and dexrazoxane (ICRF-187).

143 both groups received 350 mg/m(2) intravenous irinotecan every 3 weeks (300 mg/m(2) if aged >/=70 year

144 as infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) or fluorouracil, leucovorin, and ox

145 ith first-line fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus cetuximab in the Cetuximab Com

146 ith first-line fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus cetuximab in the Cetuximab Com

147 combination of leucovorin, fluorouracil, and irinotecan (FOLFIRI) regimen is superior as first-line t

148 f cetuximab to fluorouracil, leucovorin, and irinotecan (FOLFIRI) significantly improved overall surv

149 compared with fluorouracil, leucovorin, and irinotecan (FOLFIRI).

150 h fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) showed superior efficacy as compa

151 r sensitivity to FOLFIRI [5-fluorouracil(FU)+irinotecan+folinic acid] than to FOLFOX (5-FU+oxaliplati

152 e combination regimen was 15 mg/m(2)/d of IV irinotecan for 5 days of 2 consecutive weeks and 112.5 m

153 -line FOLFIRI (leucovorin, fluorouracil, and irinotecan) for metastatic colorectal cancer in patients

154 tudy design included two dose levels (DL) of irinotecan given intravenously once daily for 5 consecut

155 IV irinotecan given with 12 days of oral gefitinib is well

156 ents (3.8%) patients in the bevacizumab-plus-irinotecan group (grades 1, 2, and 4, respectively).

157 ths, two in the IrPan group and three in the irinotecan group.

158 [12%]; p<0.0001) than did individuals in the irinotecan group.

159 more commonly in the IrPan group than in the irinotecan group.

160 , and fatigue (8.9%) in the bevacizumab-plus-irinotecan group.

161 ns continued on standard-dose cetuximab plus irinotecan (group C).

162 e bevacizumab-alone and the bevacizumab-plus-irinotecan groups, estimated 6-month progression-free su

163 Camptothecin (CPT)-11 (irinotecan) has been used widely for cancer treatment, p

164 Both Irinotecan/HAS2 (Hyaluronan synthase 2) and Bevacizumab/

165 n with panitumumab) vs 4.0 [2.7-7.5] months (irinotecan); HR, 0.93 [95% CI, 0.64-1.37]; P = .73; inte

166 tment (85 mg/m2 of oxaliplatin, 180 mg/m2 of irinotecan hydrochloride, 400 mg/m2 of leucovorin calciu

167 identified a patient prescribed a regimen of irinotecan hydrochloride, cetuximab, and ramucirumab for

168 is of new liver and lung metastases in 2010, irinotecan in 2011, and then cetuximab until progression

169 in combination with cisplatin, docetaxel, or irinotecan in a multi-institutional, randomized, phase I

170 Nanoliposomal irinotecan in combination with fluorouracil and folinic

171 lus cetuximab in the Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorect

172 lus cetuximab in the Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorect

173 se (MTD) and dose-limiting toxicity (DLT) of irinotecan in patients with advanced solid tumors strati

174 ated adjuvant chemotherapy containing FU and irinotecan in patients with MMR deficient (MMR-D) colon

175 ess cetuximab monotherapy and cetuximab plus irinotecan in patients with molecularly selected (G13D m

176 was to assess the addition of panitumumab to irinotecan in pretreated advanced colorectal cancer.

177 e the cytotoxicity of the DNA damaging agent irinotecan in TNBC using xenotransplant tumor models.

178 , FOLFIRI (folinic acid, 5-fluorouracil, and irinotecan) in a 3D printed fluidic device.

179 0203, FOLFIRI (fluorouracil, leucovorin, and irinotecan) in study 20050181, or best supportive care i

180 f bevacizumab, alone and in combination with irinotecan, in patients with recurrent glioblastoma in a

181 irmed by encapsulating a cancer therapeutic, irinotecan, in the compartment containing the acetal-mod

182 l (5-FU), or SN-38 (the active metabolite of irinotecan) induced Notch-1 intracellular domain (NICD)

183 nd IL-18, which mediate tissue injury during irinotecan-induced mucositis in mice.

184 s and the role of inflammasome activation in irinotecan-induced mucositis.

185 ole of glucuronidation in protecting against irinotecan-induced toxicity.

186 Mucositis in mice was induced by irinotecan injection in C57BL/6 wild-type, gp91phox(-/-)

187 Both doxorubicin (Dox) and irinotecan (Iri) elution kinetics for all bead sizes eva

188 otherapy either alone or in combination with irinotecan (IRI) in the Federation Francophone de Cancer

189 rms were evaluated: IFL (fluorouracil [FU] + irinotecan [IRN]), FOLFOX (FU + oxaliplatin), and IROX (

190 Irinotecan is a useful chemotherapeutic for the treatmen

191 e/dexamethasone and systemic oxaliplatin and irinotecan is an effective regimen for the treatment of

192 Nanoliposomal irinotecan is approved by the FDA for gemcitabine-refrac

193 use protracted administration of intravenous irinotecan is costly and inconvenient, we sought to dete

194 sk of severe neutropenia from treatment with irinotecan is related in part to UGT1A1*28, a variant th

195 Irinotecan is used clinically for the treatment of color

196 Irinotecan is used for colorectal cancer treatment but t

197 ct, and it was increased in combination with irinotecan, leading to tumor regression and replacement

198 leucovorin, and oxaliplatin was superior to irinotecan, leucovorin, and fluorouracil as a first-line

199 d ABCG2 expression to increase intracellular irinotecan levels in pancreatic cancer.

200 nfusion via a hepatic arterial pump or port, irinotecan-loaded drug-eluting beads, and radioembolizat

201 In this issue of the JCI, Liu et al. use irinotecan-loaded nanoparticles to treat pancreatic aden

202 nistration of iRGD enhanced the uptake of an irinotecan-loaded silicasome carrier that comprises lipi

203 monstrate that iRGD enhances the efficacy of irinotecan-loaded silicasome-based therapy and may be a

204 served with the combination of cetuximab and irinotecan may reflect true drug synergy or persistent i

205 ral location to receive either nanoliposomal irinotecan monotherapy (120 mg/m(2) every 3 weeks, equiv

206 acil and folinic acid (n=117), nanoliposomal irinotecan monotherapy (n=151), or fluorouracil and foli

207 ffer between patients assigned nanoliposomal irinotecan monotherapy and those allocated fluorouracil

208 received fluoropyrimidines, oxaliplatin, and irinotecan; most [91%] had also received cetuximab) were

209 miting in one of six patients treated at the irinotecan MTD of 60 mg/m2/d.

210 tic cancer, combining PDP with nanoliposomal irinotecan (nal-IRI) prevented tumor relapse, reduced me

211 r activity of a nanoliposomal formulation of irinotecan (nal-IRI).

212 ffer whether second-line therapy begins with irinotecan or FOLFOX4.

213 nse) to randomly allocate patients to either irinotecan or IrPan.

214 edictive biomarker for the benefit of adding irinotecan or oxaliplatin to FU.

215 A fluoropyrimidine plus irinotecan or oxaliplatin, combined with bevacizumab (a

216 ased chemoresistance to fluorouracil but not irinotecan or oxaliplatin.

217 gnosis but is not a predictive biomarker for irinotecan or oxaliplatin.

218 he introduction of nanocarriers that deliver irinotecan or paclitaxel.

219 itabine and/or bevacizumab, cetuximab and/or irinotecan, or erlotinib resulted in increased antitumor

220 dity profile; fluorouracil plus oxaliplatin, irinotecan, or nanoliposomal irinotecan should be offere

221 were treated with either the cytotoxic drug, Irinotecan, or saline as control.

222 rectal radiotherapy, and the use of combined irinotecan/oxaliplatin chemotherapy were more frequent i

223 4.3 months (95% CI, 12.0 to 15.9 months) for irinotecan (P = .38; hazard ratio = 0.92; 95% CI, 0.8 to

224 nitial dose, then 250 mg/m(2) per week) plus irinotecan, patients with </= grade 1 skin reactions wer

225 ombination of fluorouracil, oxaliplatin, and irinotecan plus bevacizumab (FOLFOXIRI-Bev) is an establ

226 e-arm design including irinotecan (control), irinotecan plus ciclosporin, and irinotecan plus panitum

227 and continuous-infusion fluorouracil (ECF), irinotecan plus cisplatin (IC), or FOLFOX (oxaliplatin,

228 Irinotecan plus cisplatin (IP) improved survival over et

229 were randomly assigned either nanoliposomal irinotecan plus fluorouracil and folinic acid (n=117), n

230 survival in patients assigned nanoliposomal irinotecan plus fluorouracil and folinic acid was 6.1 mo

231 y in the 117 patients assigned nanoliposomal irinotecan plus fluorouracil and folinic acid were neutr

232 ith FOLFIRINOX chemotherapy (oxaliplatin and irinotecan plus leucovorin and fluorouracil).

233 incidence of early nausea for patients given irinotecan plus oxaliplatin (IROX) compared with those g

234 had longer overall survival than both IROX [irinotecan plus oxaliplatin] and IFL [irinotecan and bol

235 (control), irinotecan plus ciclosporin, and irinotecan plus panitumumab (IrPan) groups.

236 toneal dosing of the clinically used prodrug irinotecan produces high initial and local concentration

237 followed by later treatment with taxanes and irinotecan, provides some benefit.

238 inotecan treatment, we also demonstrate that irinotecan reduced the tumoral expression of monocarboxy

239 f cetuximab dose escalation in patients with irinotecan-refractory metastatic colorectal cancer who h

240 the mechanisms of cancer cell resistance to irinotecan remains poorly understood.

241 n systemic chemotherapy using oxaliplatin or irinotecan remains unknown for patients with resected li

242 identify perturbed chromatin acetylation in irinotecan resistance and establish HDAC inhibitors as p

243 ated colorectal cancer (CRC) cell models for irinotecan resistance and report that resistance is neit

244 Selection of irinotecan resistance in colon carcinoma cells led to a

245 Subsequent treatment of irinotecan-resistant, but not parental, CRC cells with h

246 tter two could be employed following loss of irinotecan response.

247 may reflect true drug synergy or persistent irinotecan sensitivity.

248 us oxaliplatin, irinotecan, or nanoliposomal irinotecan should be offered to patients with first-line

249 Nanoliposomal irinotecan showed activity in a phase 2 study in patient

250 FL118 was no better than the active form of irinotecan, SN-38 at 1 microM, FL118 effectively inhibit

251 PDT and a subclinical dose of nanoliposomal irinotecan synergistically inhibited tumor growth by 70%

252 e addition of temsirolimus or dinutuximab to irinotecan-temozolomide in patients with relapsed or ref

253 INTERPRETATION: Irinotecan-temozolomide-dinutuximab met protocol-defined

254 Irinotecan-temozolomide-dinutuximab shows notable anti-t

255 Of the 17 patients assigned to irinotecan-temozolomide-dinutuximab, nine (53%; 95% CI 2

256 inotecan-temozolomide-temsirolimus and 17 to irinotecan-temozolomide-dinutuximab.

257 ng 35 patients, 18 were randomly assigned to irinotecan-temozolomide-temsirolimus and 17 to irinoteca

258 e combination meriting further study whereas irinotecan-temozolomide-temsirolimus did not.

259 Of the 18 patients assigned to irinotecan-temozolomide-temsirolimus, one patient (6%; 9

260 Among these, the irinotecan/temozolomide combination induced strong tumor

261 anthracycline, 4 cisplatin, 1 paclitaxel, 1 irinotecan) that meet inclusion criteria, with a total o

262 which tested the addition of panitumumab to irinotecan therapy in patients with KRAS wt aCRC who exp

263 e mCRC who had progressed within 6 months of irinotecan therapy were randomly assigned to cetuximab 4

264 metastatic colorectal cancer, all with prior irinotecan therapy.

265 ssions that accurately predicted for optimal irinotecan timing.

266 ownregulation of the main cellular target of irinotecan TOP1 nor upregulation of the key TOP1 PDB rep

267 an tumor xenograft models in comparison with irinotecan, topotecan, doxorubicin, 5-FU, gemcitabine, d

268 Moreover, we found that irinotecan treatment dramatically altered the compositio

269 Irinotecan treatment is associated with mucositis, which

270 However, the full potential of irinotecan treatment is hindered by several cancer cell

271 Irinotecan treatment resulted in increased IL-1beta and

272 The net result of combined lurbinectedin and irinotecan treatment was a complete reversal of EWS-FLI1

273 ere euthanized 7 days after the beginning of irinotecan treatment, and small intestines were collecte

274 Although PDT potentiated irinotecan treatment, we also demonstrate that irinoteca

275 intestinal toxicity was observed relative to irinotecan treatment.

276 The topoisomerase I (TOP1) inhibitor irinotecan triggers cell death by trapping TOP1 on DNA,

277 umors in a phase II study of bevacizumab and irinotecan underwent brain MR and (18)F-FDG PET within 2

278 ol AHEP0731 and treated with vincristine and irinotecan (VI).

279 chemotherapy that incorporated the assigned irinotecan-vincristine regimen.

280 erence in the response rates between the two irinotecan-vincristine schedules.

281 ts: Of the 696 PICCOLO trial patients in the irinotecan-vs-irinotecan with panitumumab randomization,

282 The starting dose of irinotecan was 700 mg in patients with the *1/*1 and *1/

283 A single oral dose of irinotecan was given on day 9 of course 2 to allow pharm

284 The 21-day regimen of oral gefitinib with irinotecan was not tolerated.

285 y in combination with the DSB-inducing agent irinotecan was observed in a disease relevant model.

286 Irinotecan was then escalated from 30 to 60 mg/m2/d.

287 The time-dependent penetration of irinotecan was visualized and the localization of three

288 plus FOLFIRI (fluorouracil, leucovorin, and irinotecan) was superior to placebo plus FOLFIRI in prev

289 Bevacizumab, alone or in combination with irinotecan, was well tolerated and active in recurrent g

290 inations of oxaliplatin, 5-fluorouracil, and irinotecan were investigated for metastatic colorectal c

291 ontaining fluorouracil, capecitabine, and/or irinotecan were randomly assigned to receive octreotide

292 the camptothecin derivatives, topotecan, and irinotecan, which are used to treat human cancers.

293 s 23% (95% CI, 9% to 40%) for cetuximab plus irinotecan with a hazard ratio of 0.74 (95% CI, 0.42 to

294 and subsequent fluorouracil, leucovorin, and irinotecan with or without bevacizumab in the second-lin

295 PICCOLO trial patients in the irinotecan-vs-irinotecan with panitumumab randomization, 331 had suffi

296 , median (IQR) PFS was 3.2 [2.7-8.1] months (irinotecan with panitumumab) vs 4.0 [2.7-7.5] months (ir

297 range [IQR]) PFS was 8.3 [4.0-11.0] months (irinotecan with panitumumab) vs 4.4 [2.8-6.7] months (ir

298 The regimens of weekly irinotecan with platinum have been used for treatment of

299 ssigned to one of two treatment schedules of irinotecan with vincristine: regimen 1A included irinote

300 -970, enhanced the in vivo tumor response to irinotecan without additional toxicity.